# Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

> **NCT05020392** · PHASE3 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Burkitt Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells
- **DRUG:** Fludarabine-based chemotherapy + CAR-T-CD19 Cells

## Key facts

- **NCT ID:** NCT05020392
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-14
- **Primary completion:** 2023-10-13
- **Final completion:** 2024-10-13
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020392, "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05020392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*